MAS

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Metabolism, Obesity, Euronext Growth, Skeletal muscle, Patient, Nature Biotechnology, Weight loss, Trial of the century, OBA, Facial muscles, Sarcopenia, Therapy, MAS, Pharmaceutical industry

These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.

Key Points: 
  • These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.
  • We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
  • The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024.
  • Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.

Scale Computing Approved on Climb Channel Solutions’ OMNIA Partners/NCPA and GSA Contracts

Retrieved on: 
Tuesday, April 2, 2024
Government, Growth, Bangladesh Administrative Service, Partnership, NCPA, Education, Acquisition, GSA, Public sector, Climbing, MAS, Airline

"The growing importance of the government market cannot be overstated for Scale Computing, and our expanded partnership with Climb Channel Solutions through the OMNIA Partners/NCPA and GSA contracts is a pivotal move towards addressing the unique requirements of the public sector,” said Jeff Ready, CEO and Co-Founder of Scale Computing.

Key Points: 
  • "The growing importance of the government market cannot be overstated for Scale Computing, and our expanded partnership with Climb Channel Solutions through the OMNIA Partners/NCPA and GSA contracts is a pivotal move towards addressing the unique requirements of the public sector,” said Jeff Ready, CEO and Co-Founder of Scale Computing.
  • “We are pleased to see more vendors and partners participate in Climb’s OMNIA Partners/NCPA and GSA contracts as a part of their growth strategies” said Dale Foster, CEO at Climb Channel Solutions.
  • "Climb leverages government contracts to deliver best-in-class security and IT solutions across government, healthcare, and education sectors nationwide.
  • We are excited to add Scale Computing amidst a major shift in the channel, providing more opportunities to established and new partners.”

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Retrieved on: 
Monday, April 8, 2024
Research, Technology, Semiconductor, Genetics, Health Technology, Nanotechnology, Biotechnology, Hardware, Health, Science, CNRS, CPMAS, 2000s, HCN, Membrane, Corporation, DNP, NMR, Bruker, Hertz, Protein, Multimedia, MAS, BRKR, WB, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
  • Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries.
  • The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates.
  • In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
Tuesday, April 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

TerraPay Receives MPI License from the MAS

Retrieved on: 
Monday, April 8, 2024
Money, Payment, MAS, MPI, Commerce

SINGAPORE, April 8, 2024 /PRNewswire/ -- TerraPay, a global money movement company, has been granted a Major Payment Institution (MPI) License under the Payment Services Act 2019 by the Monetary Authority of Singapore (MAS) — a significant milestone solidifying TerraPay's position as a cross-border payments powerhouse.

Key Points: 
  • SINGAPORE, April 8, 2024 /PRNewswire/ -- TerraPay, a global money movement company, has been granted a Major Payment Institution (MPI) License under the Payment Services Act 2019 by the Monetary Authority of Singapore (MAS) — a significant milestone solidifying TerraPay's position as a cross-border payments powerhouse.
  • TerraPay now has 11 licenses and 19 regulatory approvals in 30 markets, globally.
  • Commenting on the announcement, Sheshagiri Malliah, Managing Director - Terra Payment Services Pte Ltd ("TerraPay") said, "Being granted this license by the Monetary Authority of Singapore is a big milestone for TerraPay, especially as we expand our reach and services across geographical borders.
  • As the heart of thriving international trade and commerce, Singapore has always been a strategic location for TerraPay.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

GSR Obtains Major Payment Institution Licence from Monetary Authority of Singapore

Retrieved on: 
Thursday, April 4, 2024
Cryptocurrency, Professional Services, Finance, OTC, Ecosystem, Money, GSR, MAS, MPI

GSR , the global cryptocurrency trading firm and liquidity provider, today announced that its Singapore subsidiary, GSR Markets Pte.

Key Points: 
  • GSR , the global cryptocurrency trading firm and liquidity provider, today announced that its Singapore subsidiary, GSR Markets Pte.
  • Ltd. (GSR Singapore) has received a Major Payment Institution (MPI) licence from the Monetary Authority of Singapore (MAS).
  • This milestone follows GSR receiving the in-principle approval for a MPI licence from MAS in September 2023 .
  • With this licence from one of the world’s most respected regulators, our clients should have even greater confidence in the rigour and quality of our standards, policies and procedures,” added Xin Song, GSR Group COO and CEO of GSR Singapore.

Rebellion Defense Software Products and Services Now Available via GSA Multiple Award Schedule

Retrieved on: 
Wednesday, March 27, 2024
Technology, Other Transport, Defense, Transport, Telecommunications, Other Defense, Software, Contracts, Networks, Internet, Hardware, Semiconductor, Data Management, Security, Organization, General Services Administration, Intelligence, Acquisition, AI, United States Air Force, National Nuclear Security Administration, GSA, United States Indo-Pacific Command, Mission, Government, MAS, Risk management

Rebellion Defense , a leading U.S. defense software and services company, proudly announces it was awarded a Multiple Award Schedule (MAS) contract by the General Services Administration (GSA) in an unprecedented 41 days, marking a significant milestone in the company’s journey.

Key Points: 
  • Rebellion Defense , a leading U.S. defense software and services company, proudly announces it was awarded a Multiple Award Schedule (MAS) contract by the General Services Administration (GSA) in an unprecedented 41 days, marking a significant milestone in the company’s journey.
  • Rebellion Defense underwent rigorous vetting, from technical assessments to past performance validation, culminating in a remarkable achievement for a four-year-old start-up.
  • “As a defense-first company, we prioritize hiring exceptional individuals with deep federal expertise,” said Ben FitzGerald, Chief Executive Officer at Rebellion Defense.
  • “Their dedication and focus exemplify our shared commitment to excellence and to strengthening our nation’s competitive edge swiftly and efficiently.”
    Rebellion’s GSA Schedule offers customers multiple benefits:
    This contract covers all Rebellion software products, including Iris and Nova , as well as Mission Engineering services.